Catalent appoints clinical supply services leader.

Byline: Anthony Vecchione

Somerset-based Catalent, a provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products, announced Wednesday the appointment of Ricci Whitlow as president, Clinical Supply Services.

Whitlow succeeds Paul Hegwood, who, following a period of transition, plans to retire in March 2020 after a career of nearly 45 years in operations, business development and engineering roles. As president of the business unit, she will have global responsibility for all aspects of Catalent's clinical supply business, which in fiscal year 2019 generated $321.4 million in revenue and $84.4 million in segment EBITDA (earnings before interest, tax, depreciation and amortization).

Whitlow's position will continue to report to President and Chief Operating Officer Alessandro Maselli.

"The clinical supply business is a key component of Catalent's business strategy, and Ricci rejoins the company following the launch of new initiatives that are helping to guide sponsors in optimizing their clinical trial supply planning and will provide them with new direct-to-patient supply options," said Maselli." Ricci's expertise in operations and manufacturing, as well as her previous experience at Catalent, make her the ideal person to strengthen and grow this business as the needs of global trials evolve."

Maselli added: "We would like to thank Paul for his service to Catalent...